Functional Connectomic Approach to Studying Selank and Semax Effects
Comparison in people · 2020
- What was studied
- 52 healthy participants; separate Semax, Selank and placebo conditions
- Main finding
- A 52-person fMRI study found drug-related differences in amygdala–temporal connectivity after Semax, Selank or placebo; it did not quantify improved anxiety or cognition.
Reported findings and study design
A 52-person fMRI study found drug-related differences in amygdala–temporal connectivity after Semax, Selank or placebo; it did not quantify improved anxiety or cognition.
52 healthy participants; resting-state fMRI before treatment and at 5 and 20 minutes.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Functional connectivity | Between-group and between-condition differences involving right amygdala and right temporal regions | Brain-imaging finding; no clinical symptom response rates |
| Participants | 52 across Semax, Selank and placebo | Arm counts not supplied in indexed abstract |
| Assessment schedule | Baseline; 5 and 20 minutes |
Connectivity changes are not proof of improved executive function or treatment of anxiety. No numerical clinical effect is available in this abstract.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- This compares separate interventions; it is not a Semax-plus-Selank combination trial.
- No demonstrated cognitive-performance gain follows from the imaging endpoint.
- Potential overlap with earlier imaging publications remains to be checked.
Source details
Journal publication
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Sources checked
Citation
Ya R Panikratova, I S Lebedeva, O Yu Sokolov, A D Rumshiskaya, D A Kupriyanov, N V Kost, N F Myasoedov. Functional Connectomic Approach to Studying Selank and Semax Effects Dokl Biol Sci. 490(1):9–11
Study source ↗ · DOI 10.1134/S001249662001007X · Bibliography entry · Link to this summary
Related compounds
Semax
A synthetic heptapeptide, Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It combines residues 4–7 of adrenocorticotropic hormone (ACTH) with Pro–Gly–Pro and has been studied in ischemic stroke.
Selank
A synthetic heptapeptide, Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP). It extends the immune peptide tuftsin with Pro–Gly–Pro and has been studied in anxiety and neurobiology.